Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients

Published:March 12, 2015DOI:



      Alopecia is a common side-effect of chemotherapy and affects quality of life of cancer patients. Some patients and physicians believe that alopecia could be a surrogate marker for response to chemotherapy and impact on prognosis. However, this was never been tested in a sufficiently large cohort of ovarian cancer patients.

      Patients and methods

      We analysed retrospectively the meta-databank of four prospective randomised phase-III-trials with platinum- and taxane-based 1st-line-chemotherapy in patients with advanced epithelial ovarian cancer (EOC) regarding the impact of alopecia overall outcome.


      For 4705 (92.0%) of a total of 5114 EOC-patients alopecia was documented. They had received on median six cycle platinum-taxane chemotherapy (range 0–11) with 4186 (89.0%) having completed ⩾6 cycles. Worst alopecia grade was 0 in 2.4%, 1 in 2.9% and 2 in 94.7% of the patients. In a univariate analysis, including all patients, grade-0/1 alopecia was associated with significantly lower progression free survival (PFS) and overall survival (OS) compared to grade-2 alopecia. However when assessing only those patients who completed ⩾6 chemotherapy-cycles and hence eliminating the bias of lower total dose of treatment, alopecia failed to retain any significant impact on survival in the multivariate analysis. Merely the time point of alopecia onset was an independent prognostic factor of survival: patients who developed grade-2 alopecia up to cycle 3 had a significantly longer OS compared to patients who experienced alopecia later during therapy (hazard ratio (HR): 1.25; 95% confidence interval (CI): 1.04–1.50).


      Within a large EOC-patient cohort with 1st-line platinum- and taxane-based chemotherapy early onset alopecia appears to be significantly associated with a more favourable outcome in those patients who completed ⩾6 chemotherapy cycles. It remains to be elucidated if early onset alopecia is just a surrogate marker for higher sensitivity to chemotherapy or if other biological effects are underlying.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hawighorst-Knapstein S.
        • Fusshoeller C.
        • Franz C.
        • Trautmann K.
        • Schmidt M.
        • Pilch H.
        • et al.
        The impact of treatment for genital cancer on quality of life and body image–results of a prospective longitudinal 10-year study.
        Gynecol Oncol. 2004; 94: 398-403
        • Hackbarth M.
        • Haas N.
        • Fotopoulou C.
        • Lichtenegger W.
        • Sehouli J.
        Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study.
        Support Care Cancer. 2008; 16: 267-273
        • Erol O.
        • Can G.
        • Aydıner A.
        Effects of alopecia on body image and quality of life of Turkish cancer women with or without headscarf.
        Support Care Cancer. 2012; 20: 2349-2356
        • Carelle N.
        • Piotto E.
        • Bellanger A.
        • Germanaud J.
        • Thuillier A.
        • Khayat D.
        Changing patient perceptions of the side effects of cancer chemotherapy.
        Cancer. 2002; 95: 155-163
        • Can G.
        • Demir M.
        • Erol O.
        • Aydiner A.
        A comparison of men and women’s experiences of chemotherapy-induced alopecia.
        Eur J Oncol Nurs. 2013; 17: 255-260
        • Münstedt K.
        • Manthey N.
        • Sachsse S.
        • Vahrson H.
        Changes in self-concept and body image during alopecia induced cancer chemotherapy.
        Support Care Cancer. 1997; 5: 139-143
        • Freedman T.G.
        Social and cultural dimensions of hair loss in women treated for breast cancer.
        Cancer Nurs. 1994; 17: 334-341
        • Tierney A.J.
        • Taylor J.
        • Closs S.J.
        Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer.
        Scand J Caring Sci. 1992; 6: 75-80
        • Welch D.
        Alopecia and chemotherapy.
        Am J Nurs. 1980; 35: 83-90
        • Elis A.
        • Blickstein D.
        • Manor Y.
        • Lishner M.
        Association between alopecia and response to chemotherapy in patients with Hodgkin lymphoma.
        Ther Drug Monit. 2005; 27: 287-289
        • du Bois A.
        • Lück H.J.
        • Meier W.
        • Adams H.P.
        • Möbus V.
        • Costa S.
        • et al.
        A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
        J Natl Cancer Inst. 2003; 95: 1320-1329
        • du Bois A.
        • Weber B.
        • Rochon J.
        • Meier W.
        • Goupil A.
        • Olbricht S.
        • et al.
        Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens.
        J Clin Oncol. 2006; 24: 1127-1135
        • Pfisterer J.
        • Weber B.
        • Reuss A.
        • Kimmig R.
        • du Bois A.
        • Wagner U.
        • et al.
        Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
        J Natl Cancer Inst. 2006; 98: 1036-1045
        • du Bois A.
        • Herrstedt J.
        • Hardy-Bessard A.C.
        • Müller H.H.
        • Harter P.
        • Kristensen G.
        • et al.
        Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
        J Clin Oncol. 2010; 28: 4162-4169
      1. International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary.
        Am J Obstet Gynecol. 1987; 156: 263-264
        • Minna J.D.
        • Higgins G.A.
        • Glatstein E.J.
        Cancer of the lung.
        in: De Vita V. Hellmann S. Rosenberg S. Cancer: principles and practice of oncology. Lippincott, Philadelphia, PA1984: 536
      2. National Cancer Institute. cancer therapy evaluation program: common toxicity criteria. Available from: [publish Date: August 9, 2006].

        • Lishner M.
        • Manor Y.
        • Kitay-Cohen Y.
        • Avishay A.E.
        Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin’s disease.
        Med Hypotheses. 1999; 53: 447-449
        • Pignata S.
        • Scambia G.
        • Katsaros D.
        • et al.
        Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multicentre, open-label, phase 3 trial.
        Lancet Oncol. 2014; 1: 1-9
        • Soveri L.M.
        • et al.
        Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?.
        Eur J Cancer. 2014; 50: 2966-2974
        • Innominato P.F.
        • et al.
        Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
        Cancer. 2013; 119: 2564-2573